S'identifier

Drugs predominantly attach to plasma proteins, with only a small percentage remaining unbound. The unbound portion can be calculated as one minus the bound fraction. Acidic drugs form large, inactive complexes by reversibly binding to plasma albumin, which prevents them from diffusing across biological barriers. These drug-protein complexes act as reservoirs for the drugs. As the concentration of unbound drugs decreases, these complexes quickly dissociate to release the free drug, maintaining the unbound fraction. The quantity of protein-bound drugs relies on various factors, including the concentrations of free drug and protein, the number of binding sites, and their affinity for the drug. Due to the abundance of binding sites and indiscriminate binding, various drugs or endogenous substances may engage in competitive binding with plasma proteins. For instance, when sulfonamide competitively binds to plasma proteins, it reduces albumin's affinity for bilirubin, releasing free bilirubin and increasing the risk of bilirubin encephalopathy in newborns. In situations like exercise or infection, where free fatty acid concentrations in plasma are elevated, drugs bound to albumin may be displaced, raising the concentration of unbound drugs.

Tags

Drug DistributionPlasma Protein BindingUnbound FractionAcidic DrugsDrug protein ComplexesAlbumin BindingCompetitive BindingFree Drug ConcentrationBilirubin EncephalopathyBinding SitesDrug AffinityEndogenous SubstancesPlasma Proteins

Du chapitre 3:

article

Now Playing

3.12 : Drug Distribution: Plasma Protein Binding

Pharmacokinetics

3.9K Vues

article

3.1 : Pharmacocinétique : Vue d’ensemble

Pharmacokinetics

4.8K Vues

article

3.2 : Mécanisme d’absorption du médicament : transport membranaire passif

Pharmacokinetics

3.2K Vues

article

3.3 : Mécanisme d’absorption du médicament : transport membranaire médié par le transporteur

Pharmacokinetics

3.2K Vues

article

3.4 : Absorption des médicaments : facteurs affectant l’absorption gastro-intestinale

Pharmacokinetics

3.5K Vues

article

3.5 : Biodisponibilité : Vue d’ensemble

Pharmacokinetics

2.3K Vues

article

3.6 : Facteurs influençant la biodisponibilité : élimination au premier passage

Pharmacokinetics

5.8K Vues

article

3.7 : Bioéquivalence : Vue d’ensemble

Pharmacokinetics

860 Vues

article

3.8 : Effet de premier passage

Pharmacokinetics

4.7K Vues

article

3.9 : Évolution temporelle de l’effet du médicament

Pharmacokinetics

1.8K Vues

article

3.10 : Distribution du médicament : liaison tissulaire

Pharmacokinetics

2.3K Vues

article

3.11 : Barrières physiologiques

Pharmacokinetics

3.2K Vues

article

3.13 : Modèles à compartiments : Modèle à compartiment unique

Pharmacokinetics

2.0K Vues

article

3.14 : Modèles à compartiments : Modèle à deux compartiments

Pharmacokinetics

4.9K Vues

article

3.15 : Distribution des médicaments : Volume de distribution

Pharmacokinetics

3.6K Vues

See More

JoVE Logo

Confidentialité

Conditions d'utilisation

Politiques

Recherche

Enseignement

À PROPOS DE JoVE

Copyright © 2025 MyJoVE Corporation. Tous droits réservés.